Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 4/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701788 | 0.84 | L3MBTL1 (0.41) | LMNAWDR5L3MBTL1TSHRHTT | |
| SCHEMBL3550070 | 0.83 | LMNA (0.43) | LMNAWDR5L3MBTL1TSHRHTT | |
| SCHEMBL7972629 | 0.82 | HTT (0.46) | LMNAL3MBTL1TSHRHTTHSD11B1 | |
| SCHEMBL4033412 | 0.81 | CA1 (0.42) | LMNAWDR5L3MBTL1TSHRHTT | |
| SCHEMBL10014825 | 0.81 | WDR5 (0.46) | LMNAWDR5L3MBTL1TSHRHTT | |
| SCHEMBL7396658 | 0.79 | L3MBTL1 (0.37) | L3MBTL1TSHRHTTHSD11B1CCR2 | |
| SCHEMBL4030951 | 0.78 | WDR5 (0.50) | LMNAWDR5L3MBTL1TSHRHTT | |
| SCHEMBL18036960 | 0.76 | EPAS1 (0.52) | LMNAWDR5TSHRHTTCCR2 | |
| SCHEMBL16849133 | 0.76 | SLC9A1 (0.41) | L3MBTL1HSD11B1CCR2ALDH1A1 | |
| SCHEMBL16021167 | 0.76 | L3MBTL1 (0.45) | L3MBTL1TSHRHTTHSD11B1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276743-B1 | PYRAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND HERBICIDES CONTAINING THEM | ISHIHARA SANGYO KAISHA (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8466089-B2 | Pyrazole compounds, process for their production and herbicides containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110160062-A1 | PYRAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND HERBICIDES CONTAINING THEM | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100317528-A1 | HERBICIDE CONTAINING BENZOYLPYRAZOLE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2103215-A1 | HERBICIDE CONTAINING BENZOYLPYRAZOLE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317528-A1 | HERBICIDE CONTAINING BENZOYLPYRAZOLE COMPOUND | HDHD5, HCAR3, CBR3 | LMNA 4589/4885WDR5 274/4885L3MBTL1 738/4885 |
| US-20110160062-A1 | PYRAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND HERBICIDES CONTAINING THEM | ARSA, AADAC, PDXK | LMNA 4746/4885WDR5 1593/4885L3MBTL1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.